10/30/2026
M**A- and psilocybin-assisted therapies could be available for mainstream clinical use within the year. The question of who’s qualified to be in the treatment room when that happens is being decided right now.
As new psychedelic medicines approach FDA approval, pharmaceutical companies are arguing that psychotherapy is optional—that a licensed psychotherapist in the room is an add-on rather than a clinical necessity.
One of the reasons InnerMost exists is to help define what responsible psychedelic care actually looks like. Our Chief Medical Officer and Co-Founder, Dr. Casey Paleos, disagrees and he recently submitted a formal comment to the FDA saying so.
He just published an abbreviated version of his statement on Substack that anyone can read and share: patients, family members, people who are simply curious about where this field is headed and what’s at stake.
Read the article and subscribe: https://caseypaleosmd.substack.com/p/should-a-trained-psychotherapist
